MEDICATION ADHERENCE COMPARING TOBRAMYCIN INHALATION POWDER AND SOLUTION IN PATIENTS WITH CYSTIC FIBROSIS USING THE DUTCH PHARMO DATABASE NETWORK

被引：0
|
作者：
Overbeek, J. [2 ]
Kuiper, J. [2 ]
Evers, K. [3 ]
Putzeist, M. [3 ]
Mastoridis, P. [1 ]
Ong, S. H. [4 ]
Herk-Sukel, M. [2 ]
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] PHARMO Inst, Utrecht, Netherlands
[3] Novartis Pharma BV, Arnhem, Netherlands
[4] Novartis Pharma AG, Basel, Switzerland
来源：
PEDIATRIC PULMONOLOGY | 2015年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
460
引用
收藏
页码：365 / 365
页数：1
相关论文
共 50 条
  • [41] Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection
    Greenwood, James
    Schwarz, Carsten
    Sommerwerck, Urte
    Nash, Edward F.
    Tamm, Michael
    Cao, Weihua
    Mastoridis, Paul
    Debonnett, Laurie
    Hamed, Kamal
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2017, 11 (07) : 249 - 260
  • [42] COMPARISON OF COSTS & UTILIZATION OF AZTREONAM FOR INHALATION SOLUTION (AZLI) & TOBRAMYCIN INHALATION SOLUTION (TIS) IN CYSTIC FIBROSIS PATIENTS WITH P. AERUGINOSA INFECTION IN THE UNITED STATES
    Daines, C. L.
    Nakamura, C.
    Montgomery, B.
    Oermann, C. M.
    PEDIATRIC PULMONOLOGY, 2010, : 314 - 315
  • [43] AZTREONAM FOR INHALATION SOLUTION (AZLI) VS. TOBRAMYCIN INHALATION SOLUTION (TIS), A 6-MONTH COMPARATIVE TRIAL IN CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA
    Oermann, C. M.
    Assael, B.
    Nakamura, C.
    Boas, S. R.
    Bresnik, M.
    Montgomery, A. B.
    Pressler, T.
    PEDIATRIC PULMONOLOGY, 2010, : 327 - 327
  • [44] PULMONARY EXACERBATIONS IN THE ETOILES STUDY [A LONG-TERM SAFTEY STUDY OF TOBRAMYCIN POWDER FOR INHALATION (TIP™) IN CYSTIC FIBROSIS PATIENTS]
    Debonnett, L.
    Virella-Lowell, I
    Sommerwerck, U.
    Viegas, A. S.
    Vandemeulebroecke, M.
    Angyalosi, G.
    PEDIATRIC PULMONOLOGY, 2014, 49 : 363 - 363
  • [45] A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients
    Nikolaizik, Wilfried H.
    Vietzke, Delia
    Ratjen, Felix
    CANADIAN RESPIRATORY JOURNAL, 2008, 15 (05) : 259 - 262
  • [46] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TOBRAMYCIN INHALATION POWDER IN PATIENTS WITH CYSTIC FIBROSIS: THE EDIT TRIAL
    Galeva, I
    Higgins, M.
    Piggott, S.
    Angyalosi, G.
    PEDIATRIC PULMONOLOGY, 2011, : 344 - 345
  • [47] EASE OF USE OF TOBRAMYCIN INHALATION POWDER COMPARED WITH NEBULIZED TOBRAMYCIN AND COLISTIMETHATE SODIUM: A PHASE IV CROSSOVER STUDY IN CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA INFECTION
    Greenwood, J.
    Schwarz, C.
    Sommerwerck, U.
    Nash, E. F.
    Tamm, M.
    Cao, W.
    Mastoridis, P.
    DeBonnett, L.
    Hamed, K.
    PEDIATRIC PULMONOLOGY, 2016, 51 : 361 - 361
  • [48] Lung Clearance Index (LCI) and LEV, on the evaluation of the effect of tobramycin solution for inhalation (US) among patients *th cystic fibrosis
    Hatziagorou, Elpis
    Avramidou, Vasiliki
    Kampouras, Asterios
    Kirvasillis, Fotis
    Tsanakas, John
    Hatziagorou, Elpis
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [49] High resolution computerized tomography of the chest and pulmonary function testing in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis patients
    Nasr, Samya Z.
    Gordon, Diane
    Sakmar, Ermelinda
    Yu, Xin
    Christodoulou, Emmanuel
    Eckhardt, Boris P.
    Strouse, Peter J.
    PEDIATRIC PULMONOLOGY, 2006, 41 (12) : 1129 - 1137
  • [50] LONG-TERM SAFETY AND EFFICACY OF TOBRAMYCIN INHALATION POWDER HARD CAPSULES (TIP™) IN PATIENTS WITH CYSTIC FIBROSIS: AN EXTENSION TO THE ETOILES STUDY
    Virella-Lowell, I
    Sommerwerck, U.
    Debonnett, L.
    Viegas, A.
    Maykut, R.
    Mastoridis, P.
    Cao, W.
    Angyalosi, G.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 364 - 365
12345